Latest in cancer research
Drug approvals, treatment advances, trial results and research breakthroughs.
3 items
June
Incisionless Brain Treatment Offers New Hope for Parkinson's Patients with Medication-Resistant Tremor
A groundbreaking technology called MRgFUS (magnetic resonance-guided focused ultrasound) is offering relief for Parkinson's patients with medication-resistant tremor. Unlike traditional brain surgery, this incisionless procedure uses focused ultrasound to target tremor-causing brain circuits without implants or long recovery. Available at select leading medical centers worldwide, MRgFUS shows 50–80% tremor reduction in carefully selected patients, often with improvement visible immediately after treatment.
A New Drug May Double Survival in Pancreatic Cancer: What Patients Need to Know
Pancreatic cancer has long been one of oncology's most resistant frontiers. At ASCO 2026, results from the phase 3 RASolute 302 trial changed that narrative. The oral drug daraxonrasib nearly doubled survival in patients with previously treated metastatic pancreatic cancer, achieving a median overall survival of 13.2 months compared to 6.7 months with standard chemotherapy. Oncologists are calling it transformative. Here is what patients and families need to know.
CARsgen's Claudin 18.2 CAR-T (Satri-cel) Moves Closer to Approval in China
CARsgen's satricabtagene autoleucel (satri-cel) is under priority review by China's NMPA for advanced gastric and gastroesophageal junction cancer, and it could be the world's first CAR-T therapy approved for a solid tumor. Here's what the data shows and what it means for patients.